AstraZeneca Förvaltning

Förvaltning kriterier kontrolleras 3/4

AstraZeneca VD är Pascal Claude Soriot, utsedd i Oct 2012, har en mandatperiod på 13.58 år. totala årliga ersättningen är $ 23.85M, bestående av 8.7% lön 91.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.023% av företagets aktier, värda $ 66.49M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 8.6 år respektive 7.3 år.

Viktig information

Pascal Claude Soriot

Verkställande direktör

US$23.9m

Total ersättning

VD-lön i procent	8.73%
Anställning som VD	13.6yrs
Ägande av VD	0.02%
Ledningens genomsnittliga anställningstid	8.6yrs
Styrelsens genomsnittliga mandatperiod	7.3yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Apr 29

AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold

Summary AstraZeneca delivered robust Q1 2026 results, with revenues up 8% year-on-year and operating profit rising 17%. AZN's oncology division remains a powerhouse, driving ~45% of revenues, with six blockbuster drugs and a deep pipeline supporting long-term growth. Despite Farxiga's looming US patent expiry, rare disease and oncology divisions are expected to offset declines, targeting overall $80bn annual revenues by 2030. I view AZN as a solid long-term buy-and-hold, anticipating at least 30% share price appreciation by 2030, though near-term upside appears limited. Read the full article on Seeking Alpha

Analys av ersättningar till VD

Hur har Pascal Claude Soriot:s ersättning förändrats jämfört med AstraZeneca:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Mar 31 2026	n/a	n/a	US$10b
Dec 31 2025	US$24m	US$2m	US$10b
Sep 30 2025	n/a	n/a	US$9b
Jun 30 2025	n/a	n/a	US$8b
Mar 31 2025	n/a	n/a	US$8b
Dec 31 2024	US$21m	US$2m	US$7b
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$22m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b

Ersättning vs marknad: Pascal Claude s total kompensation ($USD 23.85M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 14.80M ).

Ersättning vs inkomst: Ersättningen från Pascal Claude har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Pascal Claude Soriot (66 yo)

13.6yrs

Anställning

US$23,854,522

Kompensation

Mr. Pascal Claude Roland Soriot, M.B.A., D.V.M., is Director of Agilent Technologies, Inc. from May 21, 2025. He has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Pascal Claude Soriot	CEO & Executive Director	13.6yrs	US$23.85m	0.023% $ 66.5m
Aradhana Sarin	CFO & Executive Director	4.8yrs	US$10.58m	0.0094% $ 27.4m
Pam Cheng	EVP of Global opt. & IT	10.9yrs	inga uppgifter	inga uppgifter
Joris Silon	Head of Investor Relations	less than a year	inga uppgifter	inga uppgifter
Jeffrey Pott	CHRO, Chief Compliance Officer	17.3yrs	inga uppgifter	inga uppgifter
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	13.3yrs	inga uppgifter	inga uppgifter
Susan Galbraith	Executive Vice President of Oncology R&D	no data	inga uppgifter	inga uppgifter
Iskra Reic	Executive Vice President of International	9.1yrs	inga uppgifter	inga uppgifter
David Fredrickson	Executive Vice-President of Oncology Haematology Business Unit	8.6yrs	inga uppgifter	inga uppgifter
Ruth March	Senior VP of Precision Medicine - R&D Oncology	7.3yrs	inga uppgifter	inga uppgifter
Lutz Jermutus	Head of Projects	6.9yrs	inga uppgifter	inga uppgifter
Jim Weatherall	Chief Data Scientist of BioPharmaceuticals R&D	2.3yrs	inga uppgifter	inga uppgifter

8.6yrs

Genomsnittlig anställningstid

55yo

Genomsnittlig ålder

Erfaren ledning: AZN s ledningsgrupp är erfaren och erfaren ( 8.6 års genomsnittlig anställning).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Pascal Claude Soriot	CEO & Executive Director	13.6yrs	US$23.85m	0.023% $ 66.5m
Aradhana Sarin	CFO & Executive Director	4.8yrs	US$10.58m	0.0094% $ 27.4m
Pam Cheng	EVP of Global opt. & IT	no data	inga uppgifter	inga uppgifter
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	inga uppgifter	inga uppgifter
Marcus Wallenberg	Non-Executive Director	27.1yrs	US$226.47k	0.0039% $ 11.2m
Philip John Broadley	Senior Independent Non-Executive Director	9.1yrs	US$361.27k	0.00052% $ 1.5m
Diana Louise Layfield	Independent Non-Executive Director	5.5yrs	US$218.38k	0.000090% $ 261.1k
Michel Demare	Independent Chairman	6.7yrs	US$1.28m	0.00064% $ 1.9m
Sherilyn S. McCoy	Independent Non-Executive Director	8.6yrs	US$320.83k	0.00011% $ 319.1k
Euan Ashley	Independent Non-Executive Director	5.6yrs	US$253.43k	0.00010% $ 290.1k
Shu Mok	Independent Non-Executive Director	7.3yrs	US$195.46k	0.00023% $ 667.2k
Pankaj Bhatia	Member of External Sustainability Advisory Board	no data	inga uppgifter	inga uppgifter

7.3yrs

Genomsnittlig anställningstid

64.5yo

Genomsnittlig ålder

Erfaren styrelse: AZN s styrelse anses vara erfaren ( 7.3 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/22 23:45
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

AstraZeneca PLC bevakas av 60 analytiker. 25 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
null null	ABG Sundal Collier
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

AstraZeneca Förvaltning

Förvaltning kriterier kontrolleras 3/4

Viktig information

Senaste uppdateringar av ledningen

Astrazeneca plc Announces Stepping Down of Rene Haas as Non-Executive Director, Effective April 30, 2026

AstraZeneca PLC, Annual General Meeting, Apr 09, 2026

AstraZeneca PLC Announces Directorate And Committee Changes, Effective April 9, 2026

AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit

Recent updates

Astrazeneca Announces Approval of Baxfendy as First and Only Aldosterone Synthase Inhibitor Treatment for Adults with Hypertension in the US

Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer

AstraZeneca PLC Announces Imfinzi Plus Enfortumab Vedotin Improves Event-Free Survival And Overall Survival In Bladder Cancer

AstraZeneca Receives ODAC Recognition For Truqap Combination In PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

First quarter 2026 earnings released: EPS: US$1.99 (vs US$1.88 in 1Q 2025)

AstraZeneca PLC Announces BREZTRI Approves in the US for Asthma as First and Only Triple Therapy for Patients 12 Years of Age and Older

AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold

AstraZeneca PLC Receives US Approval For Saphnelo Self-Administration As A New Autoinjector For Systemic Lupus Erythematosus

Astrazeneca plc Announces Stepping Down of Rene Haas as Non-Executive Director, Effective April 30, 2026

Alexion Astrazeneca Rare Disease Demonstrates Statistically Significant and Clinically Meaningful Reduction of Proteinuria with Ultomiris in Adults with Immunoglobulin A Nephropathy in I Can Phase III Trial

Astrazeneca plc Announces Positive Phase Iii Results for Tozorakimab in Copd

AstraZeneca PLC Demonstrates Positive Results for Efzimfotase Alfa Phase III Program

AstraZeneca PLC to Report Q2, 2026 Results on Jul 27, 2026

AstraZeneca PLC Receives EU Approval For Imfinzi As Perioperative Immunotherapy For Early Gastric And Gastroesophageal Cancers

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

AstraZeneca PLC, Annual General Meeting, Apr 09, 2026

AstraZeneca PLC Announces Directorate And Committee Changes, Effective April 9, 2026

Calquence Plus Venetoclax Approved in the Us as First All-Oral, Fixed-Duration Combination for Patients with Chronic Lymphocytic Leukemia in the 1St-Line Setting

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

AstraZeneca Announces Positive and clinically meaningful Results from the Phase III KALOS and Logos Trials for Breztri in Patients with Undundant Ast Astrazeneca's Breztri in Patients

Final dividend of US$2.17 announced

Full year 2025 earnings released: EPS: US$6.60 (vs US$4.54 in FY 2024)

AstraZeneca PLC Provides Earnings Guidance for the Fiscal Year 2026

Astrazeneca plc Provides Update on US Regulatory Review of Saphnelo Subcutaneous Administration in Systemic Lupus Erythematosus

AstraZeneca PLC (LSE:AZN) agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million.

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) acquired Modella AI, Inc.

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit

Astrazeneca and Enhertu Announce that it has Been Granted Breakthrough Therapy Designation in the US for Adult Patients with Her2-Positive Early Breast Cancer with Residual Invasive Disease in the Breast And/Or Axillary Lymph Nodes After Neoadjuvant Treatment and High Risk of Disease Recurrence

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH

AstraZeneca's New Drug Application Accepted Under FDA Priority Review in the US for Patients with Hard-To-Control Hypertension

AstraZeneca plc Announces Approval in the US for First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US

AstraZeneca Announces Positive Full Results from the Bax24 Phase III Trial

AstraZeneca PLC Reiterates Earnings Guidance for 2025

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

AstraZeneca PLC Announces Koselugo Approved in the EUfor Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1

AstraZeneca and Amgen's Tezepelumab Approves in the European Union

Daiichi Sankyo and AstraZeneca Announces Positive Results from the TROPION-Breast02 Phase 3 Trial

AstraZeneca and Amgen's Tezepelumab Approves in the US for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca, Inc. Announces Positive Results from the Matterorn Phase III Trial

AstraZeneca Furthers ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from Planned Interim Analysis of the DESTINY-Breast05 Phase III Trial

AstraZeneca Launches Direct-To-Consumer Platform to Expand Access to Medications for US Patients, Including Those Living with Chronic Conditions

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

AstraZeneca PLC Announces European Medicines Agency Recommends Koselugo for the Treatment of Plexiform Neurofibromas in Adult Patients

AstraZeneca, Inc. Provides Update on A Supplemental New Drug Application (sNDA) for Airscra

AstraZeneca plc Announces Saphnelo Met Primary Endpoint in TULIP-SC

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

AstraZeneca Announces Positive Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

AstraZeneca Launches FluMist Home, At-Home Delivery Service for FLUMIST

Astrazeneca Canada Inc. Announces Approval in Canada as First and Only Perioperative Immunotherapy for Muscle Invasive Bladder Cancer

AstraZeneca PLC Reiterates Earnings Guidance for the Fiscal Year 2025

AstraZeneca PLC Announces Positive Results from PrevaIL Phase III Trial

AstraZeneca Announces Positive High-Level Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis

AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension

European Union Approves Imfinzi®? (Durvalumab) for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer

Datroway Approves in Us for EGFRm Lung Cancer

AstraZeneca plc Announces Fixed-Term Calquence Approval in EU for 1L CLL

AstraZeneca and Daiichi Sankyo’S ENHERTU Plus Pertuzumab Showed A Median Progression-Free Survival Greater Than Three Years

Astrazeneca's Imfinzi Recommends for Approval in the Eu by Chmp as First and Only Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer

Health Canada Grants Notice of Compliance with Conditions for Tagrisso (Osimertinib) for the Treatment of Patients with Locally Advanced, Unresectable (Stage Iii) Non-Small Cell Lung Cancer

AstraZeneca 's Record Seventh Year of Plenary Data At Asco Furthers Ambition to Redefine Breast Cancer Care and Transform Outcomes in Gastric Cancer

Analys av ersättningar till VD